300436.SHE Fujian Cosunter Pharmaceutical Co Ltd
- Market cap
- CNY 12.4B
- P/E
- -
- P/B
- 14.87x
- ROE
- -16.9%
- Dividend yield
- 0.12%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300436.SHE undervalued?
Graham numberThe Graham number of Fujian Cosunter Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Fujian Cosunter Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Fujian Cosunter Pharmaceutical Co Ltd yet.
Fujian Cosunter Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Fujian Cosunter Pharmaceutical Co Ltd
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men's health, and other fields. It also provides technical services such as drug development, including the development and quality research of active pharmaceutical ingredients (APIs) and for…
Full company profileFujian Cosunter Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Fujian Cosunter Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 313M | 296M | 402M | 415M | 368M | 370M | 386M | 423M | 441M | 416M | 438M |
| Gross Profit | 272M | 258M | 336M | 320M | 244M | 230M | 223M | 236M | 239M | 259M | 265M |
| Operating Income | 69.8M | 37.0M | 12.0M | 12.5M | 15.2M | -44.5M | -160M | -295M | -165M | -85.9M | -87.8M |
| EBITDA | 74.7M | 36.0M | 24.1M | 35.5M | 36.5M | -29.3M | -167M | -140M | -30.2M | -103M | -106M |
| Net Income | 66.4M | 33.6M | 16.5M | 10.7M | 14.8M | -34.9M | -127M | -349M | -156M | -218M | -138M |
| EPS | 0.47 | 0.24 | 0.12 | 0.08 | 0.11 | -0.23 | -0.80 | -2.19 | -0.98 | -1.37 | -0.82 |
| Balance Sheet | |||||||||||
| Total Assets | 701M | 736M | 855M | 896M | 1.01B | 1.45B | 1.49B | 1.61B | 1.44B | 1.40B | 2.02B |
| Total Liabilities | 148M | 184M | 292M | 323M | 424M | 397M | 539M | 1.05B | 1.04B | 1.05B | 1.08B |
| Shareholders' Equity | 552M | 552M | 554M | 564M | 577M | 1.04B | 928M | 516M | 360M | 278M | 819M |
| Cash & Short-term Investments | 465M | 408M | 85.9M | 93.7M | 136M | 394M | 239M | 203M | 144M | 214M | 826M |
| Total Debt | 59.9M | 56.9M | 58.1M | 135M | 211M | 125M | 293M | 387M | 325M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 73.8M | 71.5M | 10.9M | 34.0M | 15.6M | -17.8M | -120M | -175M | 20.7M | -35.1M | - |
| Capital Expenditure | 82.5M | 35.6M | 229M | 67.8M | 54.5M | 174M | 196M | 201M | 67.0M | 59.5M | 66.6M |
| Free Cash Flow | -8.66M | 35.9M | -218M | -33.8M | -38.9M | -192M | -316M | -376M | -46.3M | -94.6M | -155M |
| Ratios | |||||||||||
| ROE | 12.0% | 6.1% | 3.0% | 1.9% | 2.6% | -3.3% | -13.7% | -67.5% | -43.4% | -78.5% | -16.9% |
| ROA | 9.5% | 4.6% | 1.9% | 1.2% | 1.5% | -2.4% | -8.5% | -21.6% | -10.9% | -15.6% | -6.8% |
| Net Profit Margin | 21.2% | 11.3% | 4.1% | 2.6% | 4.0% | -9.4% | -33.0% | -82.5% | -35.4% | -52.3% | -31.5% |
| Debt to Equity | 0.11x | 0.10x | 0.10x | 0.24x | 0.37x | 0.12x | 0.32x | 0.75x | 0.90x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Fujian Cosunter Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.12%
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 4, 2018
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 15.4M | 0.10 | - |
| 2024 | CNY 17.4M | 0.11 | - |
| 2023 | CNY 17.4M | 0.11 | - |
| 2022 | CNY 10.4M | 0.07 | - |
| 2021 | CNY 9.17M | 0.06 | - |
| 2020 | CNY 8.84M | 0.06 | 59.6% |
| 2019 | CNY 7.37M | 0.05 | 68.7% |
| 2018 | CNY 15.2M | 0.11 | 92.4% |
| 2017 | CNY 35.4M | 0.25 | 105.6% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 20:10 on Sep 16, 2015.
Who owns Fujian Cosunter Pharmaceutical Co Ltd
- Insiders 46.01%
- Institutions 0.09%
- Public & others 53.90%
- Shares outstanding 168M
- Free float 97.9M
Fujian Cosunter Pharmaceutical Co Ltd company profile
- Company name
- Fujian Cosunter Pharmaceutical Co Ltd
- Ticker
- 300436.SHE
- ISIN
- CNE100001YZ0
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 715
- Fiscal year end
- December
- Address
- Building 16, Phase II, Fuzhou, China, 350003
- Phone
- 86 591 3826 5199
- Website
- cosunter.com
About Fujian Cosunter Pharmaceutical Co Ltd
Fujian Cosunter Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of pharmaceutical products in China. The company offers drugs for anti-HBV, liver diseases, hepatobiliary disease drugs, metabolism and digestive system, respiratory, cardiovascular, men's health, and other fields. It also provides technical services such as drug development, including the development and quality research of active pharmaceutical ingredients (APIs) and formulation processes. Fujian Cosunter Pharmaceutical Co., Ltd. was founded in 2001 and is headquartered in Fuzhou, China.
Fujian Cosunter Pharmaceutical Co Ltd management
9- Mr. Guoping LiChairman & GM · born 1968
- Mr. Jianhui GuanFinance Director · born 1976
- Mr. Fuhu HuangCOO & Director · born 1976
- Mr. Chenming ZhuangDeputy GM & Director · born 1976
- Dr. Hu KeChief Scientist · born 1970
- Mr. Qinghe ZhangDeputy GM & Board Secretary · born 1987
- Mr. Bing Xiang ZengDeputy General Manager · born 1963
- Mr. Yan Ru HuDeputy General Manager · born 1984
- Yan Hong LinAccounting Supervisor